Introduction {#sec1}
============

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections have revolutionized the treatment of neovascular age-related macular degeneration (nAMD).[@bib1] ^,^ [@bib2] Landmark clinical trials have demonstrated that, not only can anti-VEGF injections stabilize disease, but that initial and prolonged visual gains are also common.[@bib3] ^,^ [@bib4]

Treatment of nAMD however requires frequent intravitreal injections. Although the early pivotal trials employed a monthly injection regimen, given the difficulties with such intensive treatment, other more flexible regimens have since been developed, with pro re nata (PRN) and a treat-and-extend (T&E) protocols the most commonly employed.[@bib2]

Real-world evidence however suggests that even with these "less taxing" alternate dosing regimens, outcomes seen in practice mostly do not reach the levels achieved in trial settings, with the discrepancy possibly due to lack of adherence to clinical trial regimens (defined in this paper as non-adherence) or lack of persistence with following recommended clinical trial regimens over time (defined as non-persistence). For example, a recent meta-analysis of real-world observational data based on approximately 26,000 patients reported a mean visual gain of only +5.0 Early Treatment of Diabetic Retinopathy Study (EDTRS) letters after 12 months of treatment, with a mean number of 5.4 injections over 8.3 visits.[@bib5] This is well below the +11.3 letters seen in the ANCHOR trial with monthly intravitreal ranibizumab,[@bib6] +8.9 letters in VIEW1/VIEW 2 studies[@bib7] with every 8 weeks intravitreal aflibercept. Long term results from both clinical trials and registry data also confirm this finding, with more frequent injections consistently showing better visual outcomes.[@bib8] ^,^ [@bib9]

Given the importance of encouraging ongoing and frequent injections, there is a relative lack of awareness amongst physicians and the health community of the barriers that lead to the inter-related phenomenon of non-adherence and non-persistence of anti-VEGF treatment in nAMD in the real-world. Terminology and agreed definitions may not exist. There is even less discussion on strategies to correct or counteract these barriers. Previous studies have attempted to look at this from a local practice level or focused only on the patient experience.[@bib10] ^,^ [@bib11] However a comprehensive analysis has not been performed to date. To our knowledge this is the first systematic review of the factors affecting treatment non-adherence and non-persistence to intravitreal anti-VEGF injections in nAMD.

Methods {#sec2}
=======

This systematic review was conducted in accordance with the principles set out in the Cochrane Handbook for Systematic Reviews of Interventions.[@bib12] The protocol for this systematic review was registered with the international PROSPERO database (ID: 172653) prior to data extraction. Our results and methods are presented in reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([http://www.prisma-statement.org](http://www.prisma-statement.org/){#intref0010}, accessed 26 May 2019). All work adhered to the principles of the Declaration of Helsinki.

Eligibility criteria for considering studies for this review {#sec2.1}
------------------------------------------------------------

Studies were eligible to be included in this systematic review based on the following criteria as set out in the PICO paradigm (Patient, Intervention, Comparator and Outcome), [Table 1](#tbl1){ref-type="table"} . No eligibility restrictions were placed based on the type of anti-VEGF used or the treatment regimen employed. The minimum definitions of non-adherence and non-persistence were not set in advance, in order to allow for maximal inclusion of studies examining this topic. However, it was accepted that terms such as 'non-adherence' were synonymous with 'non-compliance'. Similarly, the term 'non-persistence' was interchangeable with 'discontinuation', 'cessation', 'lost to follow-up' or 'drop out'. Both quantitative and qualitative studies were eligible for inclusion in order to comprehensively address all aspects of the research question.Table 1Eligibility criteria based on the PICO strategyPICO ComponentInclusion CriteriaExclusion Criteria**P**PatientsStudies including patients diagnosed with nAMDStudies not reporting outcomes separately for nAMD patients**I**InterventionPatients received at least one intravitreal injection of either ranibizumab and/or bevacizumab and/or afliberceptStudies with patients receiving intravitreal injections other than anti-VEGF (eg. triamcinolone) or other treatment (eg. photodynamic therapy)**C**ComparisonNot applicableNot applicable**O**Outcomes1) Studies reporting the rates of NA/NP and factors for NA/NP.\
2) Studies addressing strategies to improve adherence and/or persistence.\
3) Studies assessing barriers to intravitreal therapyyNo specific exclusions[^1]

Studies were excluded if they assessed retinal conditions other than nAMD or evaluated interventions for nAMD other than intravitreal anti-VEGF injections. Conference abstracts were also excluded due to the inability to critically assess findings.

The primary outcome measure for this review was reasons or risk factors for treatment non-adherence and non-persistence following at least one intravitreal anti-VEGF injection. Secondary outcome measures included efficacy of strategies to improve treatment adherence and/or persistence as well as the rates of non-adherence/non-persistence itself. Further assessments were also made for factors that may be identified as general barriers to treatment.

Search methods for identifying studies {#sec2.2}
--------------------------------------

The following databases were searched: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), [clinicaltrials.gov](http://clinicaltrials.gov){#intref0015} online database and Google Scholar. Databases were last searched and results updated on 19 March 2020. In addition, the reference lists from eligible studies were also reviewed to identify any additional suitable reports. No language restrictions were imposed but if the report was not in English, the text was translated to allow for data extraction and full analysis of the risk of bias. There were no limits placed on publication date, but all studies had to be original and available in full. The search string for each database is provided in the supplementary materials (eTable 1, Supplementary materials).

References from the search results were imported into a reference management program (Zotero v5.0.66, open-source software, [https://www.zotero.org](https://www.zotero.org/){#intref0020}).

Study selection {#sec2.3}
---------------

Following the database search, the studies were screened by appraising title and abstracts. Those studies that were considered to be consistent with the search criteria were analyzed in full-text to confirm their eligibility. Two reviewers assessed the search results independently (M.O and C.H) and consensus was reached if there were any differences.

Data collection and quality of evidence assessment {#sec2.4}
--------------------------------------------------

Data from each eligible study were extracted and collected in a standardized Word (Microsoft Office, Microsoft®) document form, (eTable 2, Supplementary materials). Study origins and treatment setting (eg. country, hospital clinic), patient demographics (eg. age and baseline visual acuity), as well as treatment details including type of anti-VEGF and regimen employed were recorded. Factors or correlates reported in the study relating to treatment non-adherence or non-persistence were evaluated. Additionally, any strategies evaluated to improve the adherence or persistence were also extracted. The methodological quality of each study was assessed according to the Mixed Methods Appraisal Tool (MMAT) version 2018 as it can be used across qualitative, quantitative and mixed-methods studies.[@bib13] The overall quality and certainty of the evidence in the systematic review was evaluated using a modified GRADE approach to include qualitative evidence synthesis -- the GRADE-CERQual (Confidence in the Evidence from Reviews of Qualitative Research) tool.

Data synthesis and analysis {#sec2.5}
---------------------------

Rates of treatment non-adherence and non-persistence, where available, were summarized with the proportion of patients reported for each outcome divided by the total number at risk in the reported study population. Results were reported individually for each study. Meta-analysis was not possible due to the variations in methodology for reporting outcomes across studies (eg. differences in inclusion criteria with patient death, patient transfer for some studies but not others) and differences in time period (total non-persistence over several years versus yearly rates) and lack of raw data for some studies to enable re-analysis. As an alternative, rates were tabulated according to each study and the data range provided. Factors for non-adherence and non-persistence were also extracted from each study. These were broken down into five domains based on the standardized World Health Organization (WHO) multi-dimensions of adherence: (1) Patient-related, (2) condition-related, (3) therapy-related, (4) health care team and health system related and (5) social/economic factors.[@bib14] Factors were analyzed qualitatively according to theme, but also quantitatively with an odds ratio or percentage, where reported. Non-persistence or non-adherence due to patient death or transfer of care was excluded from analysis. If possible, intentional discontinuation by treating physician from disease stability or remission was separated from unintentional non-persistence in the analysis.

Results {#sec3}
=======

Search Results {#sec3.1}
--------------

A total of 1,436 studies were retrieved from the databases, yielding 1,284 unique records after removal of duplicates. Initial screening of the titles and abstracts identified 124 potential studies for full-text review, with 35 remaining eligible after assessment of the full-text report. Two additional studies were identified via a manual search of the reference lists, with a total of 37 reports included in the final analysis. [Figure 1](#fig1){ref-type="fig"} presents a PRISMA-based flow diagram showing the number of records identified and excluded at each stage.Figure 1PRISMA-based flow diagram of screening process.

Studies were excluded for the following reasons: (1) Did not examine nAMD specifically or included other interventions; (2) Addressed other domains in health related quality of life (HRQoL); (3) Cost-effective analysis or modelling of intravitreal injections on visual or quality of life outcomes without any correlation to impact on treatment adherence and/or persistence.

Study Characteristics {#sec3.2}
---------------------

Of the 37 eligible studies, the majority (n = 33) assessed the factors for treatment non-adherence and/or non-persistence, and a further four studies reported barriers to treatment without additional assessment of adherence/persistence.[@bib15] ^,^ [@bib16] Only two of the final studies explored strategies to improve treatment non-adherence/non-persistence. Study characteristics are summarized in [Table 2](#tbl2){ref-type="table"} .Table 2Summary characteristics of eligible studies assessing treatment adherence or persistenceStudyCountryClinic TypeStudy DesignMethodologyPatientsDrugRegimenPlanned frequency of visits**Angermann 2019**AustriaTertiaryRetrospective observationalQuantitative841NRPRNNR**Bobykin 2014**RussiaNRRetrospective observationalMixed6RBZPRN4 weeks**Boulanger-Scemama 2015**FranceTertiaryRetrospective + Telephone surveyMixed60RBZPRN4 weeks**Boyle 2018**AustraliaMixedCross-sectional surveyQualitative6NRNRNR**Curtis 2012**USNRRetrospective databaseQuantitative284,380RBZ/BEV/PEGNRNR**Droege 2013**GermanyTertiaryCross-sectional surveyQualitative77RBZPRN4 weeks**Ehlken. 2018**GermanyTertiaryRetrospective observationalMixed466RBZ/BEV/AFLPRN4 weeks**Ehlken. 2018a**GermanyMixedRetrospective + ProspectiveMixed362RBZ or BEVPRN or fixed4 weeks**Heimes 2016**GermanyNRRetrospective observationalMixed72RBZPRNNR**Holz 2015**MultinationalNRRetrospective observationalQuantitative1514RBZNRNR**Husler 2013**SwitzerlandMixedCross-sectional surveyQualitative28RBZNRNR**Jansen 2018**USLocalSelf-administered questionnaireQualitativeNRNRNRNR**Kim 2017**South KoreaTertiaryRetrospective observationalQuantitative64RBZ or BEVPRN4 to 12 weeks (8 to 24 weeks if patient refuses additional treatment)**Krivosic 2017**FranceNRRetrospective observationalQuantitative163NRNRNR**Kruger Falk 2013**DenmarkTertiaryRetrospective observationalMixed399RBZPRN4 to 6 weeks (12 to 24 weeks if no signs of disease activity)**Lad 2014**USNRRetrospective databaseQuantitative459.237RBZ or BEVNRNR**Massamba 2015**FranceTertiaryProspective cohortQuantitative29RBZPRN4 weeks**McGrath 2013**AustraliaLocalRetrospective + Telephone surveyMixed85RBZT&E4 to 8 weeks**Nunes 2010**BrazilTertiaryRetrospective + phone interviewMixed19BEVNRNR**Obeid 2018**USLocalRetrospective observationalQuantitative2003NRNRNR**Oishi 2011**JapanTertiaryRetrospective + phone interviewMixed86RBZ or PEGPRN4 to 8 weeks**Ozturk 2018**UKTertiaryRetrospective observationalMixed21AFLFixed8 weeks**Polat 2017**TurkeyNRRetrospective + Telephone surveyMixed125RBZPRN4 weeks**Ramakrishnan 2020**USMixedSecondary analysis of RCTQuantitative1178RBZ or BEVPRN or monthly4 weeks**Rasmussen 2013**DenmarkTertiaryRetrospective + Telephone surveyMixed381RBZPRN4 weeks (8 to 12 weeks if no signs of disease activity)**Rasmussen 2017**DenmarkTertiaryRetrospective observationalQuantitative269RBZ or AFLPRN4 to 6 weeks**Sii 2018**UKCross-sectional surveyQualitative53RBZ (assumed)PRN4 to 16 weeks**Subhi 2017**DenmarkTertiaryRetrospective observationalQuantitative59RBZ or AFLPRN4 weeks (ranibizumab), 8 weeks (aflibercept)**Varano 2015**MultinationalNRCross-sectional surveyQualitative143NRNRNR**Vaze 2014**AustraliaLocalRetrospective observationalQualitative105RBZNRNR**Westborg 2018**SwedenNRRetrospective observationalQuantitative472RBZ or AFLPRN, T&E or fixedNR**Wintergerst 2018**GermanyTertiaryRetrospective + Telephone surveyMixed55NRNRNR[^2]

The studies were mainly European and US-based, with a predominantly Caucasian population; only three reports involved patients from Asian countries.[@bib17], [@bib18], [@bib19] The majority of studies assessed patients treated with intravitreal ranibizumab on a PRN dosing regimen, with a few more recent studies including intravitreal aflibercept or ranibizumab on a T&E regimen, [Table 2](#tbl2){ref-type="table"}. This reflects the timing of treatment initiation of these patients, with most receiving their first anti-VEGF injection prior to 2013 (eTable 3, Supplementary materials). Most studies assessed patients treated in a tertiary hospital (university affiliated hospitals or dedicated retinal clinic) as opposed to a local clinic (general comprehensive clinic), [Table 2](#tbl2){ref-type="table"}.

Definitions {#sec3.3}
-----------

There was significant variation in the terminology and the definitions of non-adherence and/or non-persistence used across all studies. Definitions were not reported in some studies.[@bib16] ^,^ [@bib20] ^,^ [@bib21] Synonyms used for non-adherence included 'non-compliance',[@bib22] ^,^ [@bib23] 'absenteeism'[@bib24] or 'non-attendance'.[@bib25] Synonyms for non-persistence included 'treatment discontinuation/cessation'[@bib18] ^,^ [@bib26] ^,^ [@bib27] or 'lost to follow up'

Non-adherence was variably defined as: {#sec3.4}
--------------------------------------

•No treatment or consultation with a measure of visual acuity and OCT at least every 6 weeks[@bib28]•Extreme violation of prescribed treatment[@bib22]•Non-attendance of every clinic appointment[@bib19]•Receiving less than the recommended 8 injections over 12 months[@bib25]•Deviation from treatment recommendations (by patient or physician) with gap in treatment and/or consultation by \> 8 weeks[@bib29]•Visit outside of the prescribed 28 days ± 7 days window

Non-persistence was variably defined as: {#sec3.5}
----------------------------------------

•Treatment discontinuation before 12 months,[@bib30] study period[@bib26] ^,^ [@bib27] or permanently[@bib31]•No treatment or visit at clinic for more than 4 months[@bib32], 6 months[@bib15] ^,^ [@bib33] ^,^ [@bib34] or 12 months[@bib35] ^,^ [@bib36]•No follow up by any ophthalmologist for 3 months[@bib28]•No follow up within a 12 months period after receiving at least 1 anti-VEGF injection[@bib37]•Loss of follow up of at least 24 months[@bib18]

In some cases, intentional non-persistence, either due to assessed treatment futility or treatment success with inactive disease, as agreed to by patient and treating physician, was not explicitly differentiated from patients who were lost to follow up.

Prevalence of non-adherence and non-persistence {#sec3.6}
-----------------------------------------------

Non-adherence to treatment or to monitoring appointments was high with variable rates depending on how strictly it was defined (32 -- 95%).[@bib25] ^,^ [@bib28] ^,^ [@bib29] In one study, which assessed non-adherence as no treatment or consultation at least every 6 weeks when using a PRN protocol, almost all patients (n = 346, 95.6%) fulfilled this criteria over a 12 month period, with a mean of 2.1 ± 1.1 gaps.[@bib28] When determined by self-report however, rates of perceived non-adherence were much lower, with patients in a another study estimating their rates of non-adherence at 15.7% (n = 143) and caretakers estimating this at a higher 25.8% (n = 230).[@bib19] Unsurprisingly, the observed rates of non-adherence were lower in a clinical trial setting, with a secondary analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial (CATT) reporting only 10.0% of 1060 patients not attending a study visit on time when defined as an average visit interval of 4 weeks ± 7 days over a 24 month period.[@bib38] However, when the longest interval between two visits were calculated, 83.3% of patients still had at least one visit interval that was not on time.

Patients who discontinued treatment due to either disease remission or treatment futility as judged by their physician accounted for 3 -- 30% of all nAMD patients who commenced treatment. After excluding these patients, remaining rates of reported non-intentional treatment non-persistence varied between 3 -- 57% at 12 months, with lower rates when non-persistence was defined as lack of follow up visits rather than lack of anti-VEGF treatment.[@bib35] Studies of non-persistence to treatment beyond 24 months were limited, but where available, recorded very high rates of non-persistence, [Table 3](#tbl3){ref-type="table"} . Within the first 24 months, Kaplan-Meier survival curves demonstrated the onset of non-persistence for the majority of patients to occur early within the first 6 months.Table 3Reported rates of non-persistence to either treatment or monitoring visits over time (excluding patient death or transfer of care)MonthsProportion of patient non-persistent with treatment at each time point\
N, %Range\
(%)Boluanger\
(n = 201)Droege\
(n = 95)Kruger Falk\
(n=855)Rasmussen 2013\
(n = 555)Rasmussen 2017\
(n = 1027)Subhi\
(n = 116)Heimes\
(n = 191)Holz\
(n = 2227)Westborg\
(n = 932)Ehlken 2018\
(n = 362)Curtin\
(n = 284,380)Lad\
(n = 459,237)6174,094 (44.7)1237 (3.6)16 (13.8)532 (23.9)503 (50.8)68 (18.8)104,165 (53.6)213, 645 (57.4)3.6 -- 57.418112,647 (61.7)234,239 (65.6)61.7 -- 65.62410 (7.0)16 (13.8)60 (31.4)1043 (46.8)244,743 (71.0)7.0 -- 71.0364836 (4.2)6063 (31.3)60 (10.8)10.8 -- 31.3

Factors affecting treatment non-adherence {#sec3.7}
-----------------------------------------

Risk factors for non-adherence to treatment or monitoring appointments were assessed in six studies.[@bib19] ^,^ [@bib24] ^,^ [@bib25] ^,^ [@bib28] ^,^ [@bib29]

Condition-related factors such as worse visual acuity at baseline was associated with an increase (OR: 2.37, p = 0.05) in non-adherence,[@bib29] though this was not statistically significant in another study by the same authors.[@bib28] Patients whose vision improved with treatment of \> 3 lines also were more likely to be adherent (19.9% vs 12.0%, p = 0.04), though the converse (ie. loss of vision) did not appear to influence adherence pattern, in at least one study.[@bib29]

Of all patient-related variables, patient illness (21.0 -- 42.8%) accounted for a significant cause of non-adherence.[@bib19] ^,^ [@bib25] Many patients however also reported fear of injections as a major barrier to treatment (n = 30, 21%), with a small number also reporting discomfort after injections as a reason for avoidance.[@bib19]

A substantial cause for non-adherence overall related to health system factors. Patients stated sometimes forgetting their appointment (15%), the appointments were too frequent or inconvenient (10%) or there was insufficient clinic capacity with no available appointments in the time frame the patient required (47%).[@bib19] ^,^ [@bib25]

Social factors however play a significant role for most patients with many citing a lack of caretakers to take them to appointments (25.9%). Only one study examined cost factors, with less than 10% reporting financial burden as the primary issue for non-adherence.[@bib19] Seasonal factors may also play a role, with one study recording almost half of all patients (n = 29, 46%) missing at least one visit during the traditional French summer holiday period.[@bib24] This may be due to patients weighing up the benefits of holidays against their eye health.

Factors affecting treatment non-persistence {#sec3.8}
-------------------------------------------

In general, the reasons for non-persistence reflected those seen for non-adherence, [Table 4](#tbl4){ref-type="table"} .Table 4Risk factors for treatment or visit non-persistenceRisk FactorsStudiesRisk of NP\
(OR or primary reason for NP as % of responses)Effect of risk factor (Qualitative Studies)Condition-related factors**Bilaterality**Obeid\
Ehlken\
Rasmussen 2018- 0.69 OR\
3.704 OR\
3.70 OR**Worse baseline VA**Oishi\
Westborg\
Polat\
McGrath\
Bobykin\
Boulanger\
Ehlken 20188.1 OR\
1.42 OR\
0 vs. 22.6%\
42.5 vs. 51.0 letters\
OR 2.37Increased risk\
No difference\
Increased risk**Worse baseline VA in fellow eye**Westborg\
BobykinNo difference\
Decreased risk**Worse final VA**Oishi\
Sii\
Droege\
Ehlken 2018Increased risk\
Increased risk if in worse eye\
Increased risk\
Increased risk**No change in VA to treatment**Obeid\
Polat\
Vaze\
NunesIncreased risk\
Increased risk\
Increased risk\
Increased risk**Patient-related factorsOlder age**Obeid\
Ehlken 2018\
Rasmussen 2018\
Westborg\
Subhi\
Rasumssen 2013\
McGrath\
Bobykin\
Wintergerst\
Husler\
Boulanger1.58 OR 81 -- 85\
2.29 OR 86 -- 90\
3.31 OR \> 90\
OR 1.04\
OR 1.05\
13.0%\
82.0 vs. 76.6 yearsNo difference\
Increased age \> 90 years\
Increased age\
No difference\
Increased \> 80 years\
Increased**Non-Caucasian ethnicity**Obeid1.47 OR African American\
2.63 OR Asian American\
3.07 OR Other ethnicity**Systemic illness**Westborg\
Oishi\
Droege\
Rasmussen 2013\
McGrath\
Kruger Falk\
Vaze\
Nunes\
Heimes\
Wintergast\
Huser1.27 OR\
16.7%\
41.5%\
0.48 OR\
5.6%\
42.3%\
15.8%\
26%\
25%\
8.9%Increased risk**Ocular co-morbiditiesFear of injections**Polat\
Droege\
Kruger Falk\
Vaze\
Wintergast\
Huser29.6%\
5.3%\
2.8%\
11.5%\
25%\
8.9%**Perception injections not helpful or not needed**Polat\
Rasmussen 2013\
McGrath\
Kruger Falk\
Vaze\
Nunes\
Wintergast\
Huser21.6%\
10.4%\
8.3%\
23.1%\
42.1%\
11%\
21.7%Increased risk**Loss of motivation**Droege\
Heimes38%\
5%**Therapy-related factorsTreatment regimen**Hanemoto\
DroegeDecreased burden for T&E vs. PRN\
Decreased burden for PRN vs. monthly**Same day injection**KrivosicDecreased risk**Anti-VEGF drug type**Subhi\
Westborg1.45 OR RBZ vs AFLNo difference**Health systems and health-care team factorsLack of information**Nunes\
Huser\
Varano26.3%\
4.3%Increased risk**Did not like or trust physician**Kruger Falk\
Huser2.8%\
8.7%**Tertiary Centre**Westborg\
Rasmussen 20181.30 OR\
0.33 OR**Dissatisfaction with treatment center**Polat17.6%**Longer distance from home to treatment center**Polat\
Obeid\
Boyle\
McGrathR value = -0.227\
1.33 OR 21 -- 30 miles\
1.55 OR \> 30 miles\
2.48 ORIncreased risk \> 50 kmBoulangerMedian distance 18 vs 40 km**Follow-up burden**Polat\
Boyle\
Subhi\
Droege\
Rasmussen\
Kruger Falk\
Vaze\
Huser16%\
18.9%\
8.3%\
7.7%\
13.0%Increased with shorter intervals\
Increased risk\
Increased risk**Fixed appointments**Rasmussen 20180.44 OR**Difficulties with appointments**Nunes10.5%**Social/economic factorsLower socioeconomic status (SES)**Obeid1.52 OR**Social isolation or lack of carer**Polat\
Oishi\
Droege\
Wintergerst\
Huser16%\
61.5%\
8.9%Increased risk\
Increased risk**Lack of insurance status**McGrath\
Heimes\
Wintergast3%\
5%No difference**Financial burden**Polat\
Oishi\
Boyle\
Droege\
McGrath\
Vaze\
Wintergast\
Huser\
Holz20.8%\
34.8%\
8.1%\
7.7%\
10%\
13%\
2%Increased risk\
Increased risk (indirect costs)SpoonerIncreased burden (direct and indirect costs)**Lack of transport**Droege\
Rasmussen\
Vaze\
Nunes\
Heimes\
Wintergast46.3%\
7.7%\
5.3%\
38%\
27%Increased risk[^3]

Baseline visual acuity was a strong condition-specific factor, with worse baseline vision in the affected eye conferring higher risk of non-persistence of between 1.4 to 8.1 times. However, there was no consistent threshold level of visual acuity where this risk increased. Poor response to treatment and worse final visual acuity was also associated with higher rates of non-persistence. There was conflicting evidence as to whether bilateral disease was a risk factor, with some studies suggesting a 3.7 fold increased risk of discontinuation if bilateral injections were required,[@bib28] ^,^ [@bib30] whilst other studies suggested that bilaterality was a protective factor.[@bib37]

The therapy regimen may also contribute to risk of non-persistence. In a Japanese study using PRN treatment, patients who were only given a single injection, instead of three loading dose at initiation, had a higher risk of non-persistence.[@bib17]

Patient-related factors accounted for a significant cause of non-persistence. In particular, older age was an issue, with the risk increasing per decade of life. The highest risk occurred in those aged over 90 years with a 3-fold increased risk compared to those aged less than 80 years. General ill health or presence of other systemic comorbidities was also associated with risk of non-persistence independent of age. There was no difference due to patient gender or the presence of other ocular comorbidities.

Patients also reported fear of injections as a barrier to treatment, though the extent to which this was responsible varied between 3 and 30% overall. However, patient perception that the treatment was not helpful or not required was a strong risk factor, accounting for up to 42% in some series.[@bib39] However, the studies did not clarify if this was related to an expectation of improvement with treatment and subsequent disappointment when only stability of vision was achieved. This is in keeping with the finding that patients who ceased treatment often reported that lack of information about the treatment plan or the expected outcomes of treatment versus natural history.[@bib39] ^,^ [@bib40]

Health system and socio-economic-related factors however represented a significant cause for treatment non-persistence as reported by patients. Lack of transport or distance to the treatment centre was a key factor in most studies, accounting for 5 to 46% of responses. In contrast, in Denmark, where the government funds transport to the hospital, only one of the four Danish studies included in the review reported transport as an issue. Follow up burden was also reported as a significant factor, though the specifics of whether this was regimen related was not explored. The impact of cost or the financial burden on treatment persistence was quite variable, accounting for as low as 2% in one large multi-country study[@bib26] and as high as 30% in others.[@bib41] Interestingly in Sweden, where treatment for nAMD is covered by the Swedish National Insurance, 50.6% of patients reportedly still discontinued treatment during the first year of diagnosis. In some surveys, patients reported that indirect costs, related to transport for example, was more significant than the cost of the treatment itself.[@bib42] Government and insurance regulations may also play a factor. In a 2013 study from Germany, the authors examined the role of reimbursement and the approval pathway on adherence to treatment.[@bib41] At the time, patients in Germany were required to obtain approval from their insurance company prior to treatment. The cost of the injection was covered by insurance but required upfront payment before obtaining a refund. Patients were only approved for three injections at a time, before their case was reviewed. Consequently, up to a third of patients reported some difficulties with the upfront payment and a small proportion had difficulties obtaining approval or refunds. Similarly, in the real-world multi-national AURA study, researchers found there were significant differences between countries in the number of injections given, ranging from a mean of 3.2 injections over 2 years in Venezuela to 11.0 injections in Ireland.[@bib26] Although the correlation to reimbursement or approval process was not directly assessed, the authors suggested the difference in injection frequency may be due to these health system related policies.

Patients may also express a desire to stop treatment prior to actually doing so. Three studies surveyed patients, who were actively participating in treatment, on their willingness or future intentions to stop treatment and/or visits.[@bib40] ^,^ [@bib42] ^,^ [@bib43] Reasons were very similar to those reported by those who had ceased treatment, including failure to notice any improvement in vision,[@bib40] ^,^ [@bib42] ^,^ [@bib43] treatment burden on self and caretakers, as well as perceptions of being 'too old'.[@bib40] ^,^ [@bib42]

Strategies to improve treatment adherence and/or persistence {#sec3.9}
------------------------------------------------------------

There is limited evidence on the impact of strategies to improve treatment adherence or persistence, with only two studies available in the literature.[@bib15] ^,^ [@bib44] One report examined whether patients on a PRN regimen who performed their monitoring visit at a local clinic with telemedicine capabilities had better treatment adherence and increased injections compared to patients who had both monitoring and injections at the same tertiary reference centre. The outcomes suggested that the telemedicine group had greater treatment adherence with significantly greater number of monitoring visits (telemedicine group 22.8 visits vs. control group 18.4 visits, p \< 0.001) and also a greater number of injections (telemedicine group 13.9 injections vs. control group 11.1 injections, p = 0.02) over the total monitoring period. Another study examined whether providing a fast-track approach with same day injection was better than the standard protocol of booking a separate injection visit.[@bib44] In this study, the mean time between date of the monitoring visit to injection was shorter in the fast track group compared to the standard protocol group (4.1 ± 7.5 vs. 5.6 ± 18.7 days respectively). All patients surveyed in the fast track group also reported satisfaction with same day injection.

Barriers to treatment {#sec3.10}
---------------------

The literature review also identified studies that examined potential barriers to treatment, though these did not specifically address how these barriers correlated to adherence or persistence.[@bib41] ^,^ [@bib45], [@bib46], [@bib47] Additional risk factors reported in these studies include the differences in perceived treatment burden by patients or their caretakers of the various injection regimens, with lower burden index for patients on T&E regimen as compared to PRN,[@bib45] and PRN more favourable as compared to monthly.[@bib48] However, treating ophthalmologists reported difficulties of some patients in understanding the proactive nature of T&E regimens.[@bib47] Socioeconomic factors were also prominent in these studies with caretaker productivity loss (both time and financial) a significant burden.[@bib45] ^,^ [@bib46] Overall, treatment burden, both in terms of visit frequency and travel time was cited as the most significant barrier.[@bib46]

Quality assessment {#sec3.11}
------------------

Quality of each study was rated based on the Mixed Methods Appraisal Tool, with individual assessments based on qualitative, quantitative and mixed criteria (eTable 4, Supplementary materials). Most studies were limited by their retrospective nature with possible ascertainment or recall bias and lack of control group. Another frequent shortcoming was the lack of or inconsistent definitions for both the outcome and contributing factors. The rationale for why some of the assessed factors were selected was usually also not recorded. Qualitative studies also demonstrated variability in terms of the breadth of questions asked, the nature of the questioning (closed versus open-ended) and whether any validation of the questionnaire was performed. (eTable 5, Supplementary materials). The overall certainty of the evidence was synthesised according to the GRADE-CERQual assessment ([Table 5](#tbl5){ref-type="table"} ).Table 5Summary of findings and certainty of evidence using GRADE CERQual assessmentSummary of review findingContributing studiesConfidence in the evidenceExplanation of CERQual assessmentHigh rates of non-adherence and non-persistence to anti-VEGF treatment is observed, with the onset highest in the first 12 monthsLad 2014, Curtis 2012, Droege 2013, Westborg 2018, Subhi 2017, Boulanger-Scemama 2015, Rasmussen 2013, Heimes 2016, Kruger-Falk 2013ModerateModerate limitations based on variability in methodology -- in particular with regards to selection and definition of outcomes. Minor concerns regarding coherence across studies.Condition-related factors such as worse baseline visual acuity and poor response to treatment is associated with increased risk of both non-adherence and non-persistenceOishi 2011, Polat 2017, Bobykin 2014, Boulanger-Scemama 2015, Ehlken 2018, Droege 2013, Obeid 2018, Vaze 2014, Nunes 2010ModerateModerate concerns regarding methodological limitations -- in particular with regards to assessment of response to treatment. Minor concerns with coherence.Injection regimens which individualise treatment reduce patient burden and improve adherence and/or persistenceDroege 2013, Hanemoto 2017LowSerious concerns regarding data adequacy and relevance to current practiceThe most significant patient related factor affecting treatment non-adherence or non-persistence is significant systemic comorbidities and patient perception of treatment as not helpful or not neededObeid 2018, Ehlken 2018, Rasmussen 2018, Bobykin 2014, Wintergerst 2018, Husler 2013, Droege 2013, Kruger-Falk 2013, Vaze 2014, Nunes 2010, Heimes 2016, Husler 2013LowSerious concerns regarding methodological limitations -- in particular with regards to assessment of patient perception of response to treatment. Minor concerns regarding coherence across studies.Social isolation and lack of carer or transport were prominent factors for treatment non-adherence or non-persistence. Indirect costs rather than direct costs of treatment were also barriers.Oishi 2011, Droege 2013, Wintergerst 2018, Husler 2013, Heimes 2016, Polat 2017, McGrath 2015, Vaze 2014, Spooner 2018, Obeid 2018LowSerious concerns regarding methodological limitations and adequacy of data -- in particular with regards to the financial burden to patients across different health systems and settings.Health systems which allow for reduced visits (one stop service) or for monitoring in a local centre improved treatment adherence.Heimes 2016, Krivosic 2017LowSerious concerns regarding methodological limitations and adequacy of data given only two studies examined strategies to improve adherence

Discussion {#sec4}
==========

The inter-related factors of non-adherence and non-persistence to intravitreal anti-VEGF therapy is one of the major challenges in preventing vision loss from nAMD, despite the success of major clinical trials showing its effectiveness. Despite the importance, there is limited understanding of what is non-adherence and non-persistence and the factors leading to these. There is also lack of awareness of effective methods needed to alter these behaviours which can be inter-related or separate issues for each patient.

This systematic review reveals a lack of consensus definitions and terminology in the literature to identify non-persistence in nAMD patients. The World Health Organization defines 'adherence' as 'the extent to which a person's behaviour corresponds with agreed recommendations from a health care provider'.[@bib14] Most studies included here followed a PRN treatment protocol, with non-adherence to intravitreal therapy defined as either an all-or-nothing outcome of complete adherence to monthly visits or a more relaxed definition allowing deviation by more than a set number of weeks or months. However, no specific definitions for non-adherence in those using a T&E protocol were provided. Future work to develop a consensus on definitions will need to be able to straddle the differences and incorporate all treatment protocols. Similarly, there was no agreement on definitions for non-persistence, with variable timeframes and lack of differentiation as to whether the discontinuation was intentional or unintentional. For many studies, reasons listed for non-persistence included patient death, transfer of care or planned treatment cessation by the physician due to disease remission or treatment futility. Arguably, death or care transfer should be considered under a different context than for traditional causes of non-persistence, and planned treatment cessation should also be categorized separately.

The results of the review however indicate that the rate of reported non-adherence and non-persistence in nAMD is high overall at up to 60% non-persistence at 24 months follow-up in some series. The majority of non-persistence occurs within 6 to 12 months, suggesting that the decision is often made early on whether to continue with therapy. Interestingly, the rates of non-persistence were higher in one study when it was defined as no further intravitreal injections, as opposed to no monitoring visit, suggesting that some of this early non-persistence is intentional cessation of intravitreal injections, rather than lack of follow up.[@bib35] This may be due to perceived or actual sub-optimal response to treatment or issues with the injection itself, though data separating these outcomes is limited.

Conversely, once a patient has remained on treatment for several years, they are much less likely to be non-adherent or non-persistent in the future. It may be that once a routine is established and any initial barriers have been overcome, the patient is more invested in continuing their treatment. However, whether these behavioural and environmental influences on patients and their caretakers change over time has not been clearly defined in the literature.

The reasons and risk factors for non-adherence and non-persistence are multi-dimensional. As expected, strong correlations exist with patient-related factors such as increased systemic comorbidities, longer distance from home to treatment centre, lack of a caretaker to assist with transport and poorer baseline visual acuity. As expected, treatment efficacy was also a protective factor, with patients who experienced greater visual gains more likely to be both adherent and persistent. However, other factors such as bilaterality showed conflicting results with some studies suggesting poorer adherence with unilateral eye involvement[@bib37] whilst others reported worse outcomes with bilaterally treated disease.[@bib28]

Surprisingly cost was not as consistent a risk factor as expected, with financial barriers only accounting for 2 -- 30% of causes of non-persistence and less than 10% for non-adherence. This may be due to the variety of countries included in this review. For example, access to intravitreal injections is relatively easy and mostly funded by the government in places like the United Kingdom and Sweden. In contrast lower socioeconomic status was significantly associated with higher non-persistence in a study based out of the United States where insurance status significantly impacted ability to access healthcare.[@bib37] National health policy also plays a role, as different countries may have different rules on the total number of injections that can be subsidized per patient. For example, in Taiwan, patients can be reimbursed for 3 to 7 doses in each eye of either ranibizumab or aflibercept over a two-year period by an approved ophthalmologist. Switching between intravitreal agents is also restricted, so the decision on anti-VEGF type needs to be made at the initial application, regardless of treatment outcomes. The unique reimbursement rules and need for approval can therefore influence access and persistence in each country. However, even in countries where the cost of the drug itself may be funded, patients reported some financial stress related to indirect costs for treatment, such as the cost of parking[@bib10] as well productivity losses, with the caregiver needing to take time off work to accompany patients for treatment.[@bib46]

Physicians' decision-making, including tolerance to fluid on OCT imaging, may also be influenced by a patient's request to defer treatment, or to influence it. In a recent study comparing real-world clinician versus reading-centre assessment of CNV disease activity, 20% of scans were judged active by the reading centre, but no injections were given.[@bib49] Of these cases, some were assessed by the clinician as chronic degenerative cysts only whilst others were monitored in a 'watch and wait' fashion, reportedly due to patient preference.

Another unexpected finding from the review was that treatment burden did not rank as highly as expected as a cited cause for treatment non-persistence or non-adherence, accounting for only 7 to 18.9% of all cases. It may be that this terminology, when used in questionnaires, is considered too general or vague for some patients, who prefer to ascribe the difficulties to more specific barriers as 'lack of transport' or 'ill health'. This is reflected in the studies examining perceived barriers to treatment, with patients identifying visit frequency as a significant burden and preferencing regimens with less visits such as the T&E regimen.[@bib45] Patients also reported greater satisfaction with same-day injection protocols when using a PRN regimen, suggesting that treatment burden due to visit frequency was an issue.[@bib44] Phase III trials are currently underway investigating the use of ranibizumab sustained delivery devices.[@bib50] ^,^ [@bib51] Future studies looking at the adherence patterns for these longer-acting devices will be helpful in confirming if perception of treatment burden is similarly reduced.

The importance of various risk factors for non-adherence and non-persistence identified in this systematic review however may not necessarily remain static over time. The majority of studies included here assessed patients who were treated prior to 2013 and may not necessarily reflect modern practices. Almost all were using ranibizumab on a PRN regimen (eTable 3, Supplementary materials) and treatment and/or monitoring was often discontinued by the physician due to perceived lack of disease activity. Although we were not able to study the effects of different injection regimens on rates of adherence and persistence, there is increasing adoption of T&E as the preferred protocol in many countries. Changes to reimbursement criteria and updated regulatory requirements may also influence accessibility of treatment in some countries. In addition, it is likely that capacity constraints will also exert more pressures on individual clinics as intravitreal injections become more common also for other indications and the ageing populations continue to expand. Given that some patients in the review already reported difficulties with obtaining clinic appointments, delays due to overbooked clinics are likely to pose a growing problem. In contrast, better population and physician awareness about nAMD may also help identify patients at an earlier stage of disease, and baseline visual acuity may become less important of a factor over time.

Strategies to improve treatment non-adherence or non-persistence is well established in several systemic chronic diseases. In diabetes mellitus for example, previous studies have assessed a range of interventions, including modifying the insulin delivery system, simplifying the treatment regimen, improving the safety profile or providing intensive support services to promote adherence.[@bib52] ^,^ [@bib53] Within ophthalmology, strategies for adherence to glaucoma topical therapy has also been extensively investigated: namely simplifying regimens, lowering costs, patient education and involvement of the family and caretakers.[@bib54]. In contrast, there is a surprising lack of data assessing the effectiveness of different strategies on rates of treatment adherence and persistence to intravitreal injection therapy in nAMD. A limited form of telemedicine and organization of a fast-track same day injection stream are two strategies that have been evaluated thus far. Although there are significant differences between intravitreal injection therapy and other systemic and ocular diseases, lessons learnt from management of chronic systemic conditions can still be applied. For example, instead of eliciting information about non-adherence to medication as for glaucoma management,[@bib55] asking nAMD patients about their intentions or willingness to stop treatment may help to identify at risk patients and help to trigger interventions before the event. Further evaluation is required to assess whether providing education for patients and their caretakers at varying time points, for example at baseline prior to commencing treatment, after 3 months and at one year may help to clarify the goals of treatment and encourage persistence into the long term. In addition, text message reminders have been shown to be a simple cost-effective tool in the primary care setting to notify patients of upcoming healthcare appointments. This intervention can be easily applied to remind nAMD patients of their next clinic or injection visit and may be an effective solution for those 15% of respondents who reported missed appointments due to forgetfulness.[@bib19]

However, some interventions to improve adherence, whilst seemingly obvious, may prove more challenging to implement. For example, transportation was identified as a key barrier in this review. Though ideally all patients would be provided transportation to clinic appointments, the attitudes and regulations governing this may differ between health care systems. In the US, offering free transport to Medicare patients may be considered an inappropriate inducement to treatment, and therefore, legal review should be considered to understand if it is appropriate. Usually, it is not permitted. In Australia, community volunteer driver programs and Red Cross transport services are currently available initiatives. However, the vast distance between home and treatment location for many rural and regional patients makes this a deterrent. Finally, even in geographically smaller countries such as Sweden, where there is universal free transport to hospitals, some patients still struggle to engage with their treatment,[@bib20] which highlights the multifactorial nature of this problem.

The challenges of non-adherence or non-persistence to intravitreal therapy is important and not only isolated to patients with nAMD. It represents a significant problem in patients receiving anti-VEGF injections for other indications such as diabetic macular edema or retinal vein occlusion.[@bib56] However, given the relatively rapid deterioration that can happen in nAMD as compared to macular oedema from other retinovascular conditions, the effect of non-adherence on visual acuity is potentially more damaging and permanent.[@bib29]

Studies have consistently shown that results from clinical trials are not necessarily translatable to the real world, with discrepancies likely due to differences in patient population and underutilization of treatment. This systematic review reveals moderate level evidence to support the finding that high levels of non-adherence and non-persistence is observed, particularly in the first 12 months. Indeed, the current novel coronavirus (SARS-CoV-2) pandemic is a concern, as many patients are likely to have been or continue to be non-adherent during this period. The long-term impact on this population is yet to be known.

In addition, reasons for patient non-adherence and non-persistence to intravitreal injections are complex and multifactorial, though the evidence for specific factors are of low to medium level in quality. Further work is currently underway to standardize and better define these terms. We need effective tools to identify and triage the patients at risk, in order to develop meaningful interventions best suited to the individual patient at the appropriate moment in their treatment course. Current efforts to improve drug duration and efficacy may help to reduce treatment burden, but it is likely coordinated solutions that target other domains, such as transport and access to care, will be required to optimize the long-term visual outcomes for all patients.

Precis {#appsec2}
======

High rates of non-adherence and non-persistence to treatment for neovascular age-related macular degeneration are observed in this systematic review. Multiple factors are implicated, however, reporting of strategies to address this remain limited.
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Factors affecting non-adherence or non-persistence to intravitreal injection therapy for neovascular age-related macular degeneration: a systematic review
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[^1]: nAMD: neovascular age related macular degeneration; anti-VEGF: anti-vascular endothelial growth factor; NA: non-adherence; NP: non-persistence

[^2]: RBZ: ranibizumab; BEV; bevacizumab; PEG: pegaptanib; AFL: aflibercept; PRN: pro re nata; T&E: treat-and-extend; NR: Not reported

[^3]: VA: visual acuity; NP: non-persistence; OR: odds ratio; anti-VEGF: anti-vascular endothelial growth factor; vs.: versus
